Johnson & Johnson Earnings Imminent as Top Analysts Revise Forecasts

FDA approves new TECNIS PureSee lens as company prepares to report Q1 results.

Apr. 9, 2026 at 11:57am

Got story updates? Submit your updates here. ›

A highly detailed, macro-level view of the intricate mechanical components and precision engineering of a medical device, conveying a sense of the advanced technology behind Johnson & Johnson's healthcare innovations.An extreme close-up of the complex inner workings of Johnson & Johnson's latest medical device innovation, highlighting the company's technological prowess in the healthcare industry.New Brunswick Today

Johnson & Johnson (NYSE:JNJ) is set to release its first quarter earnings before the market opens on April 14. Analysts expect the company to report earnings of $2.67 per share on revenue of $23.6 billion. The company recently received FDA approval for its new TECNIS PureSee intraocular lens intended for cataract surgery.

Why it matters

Johnson & Johnson is one of the largest and most influential healthcare companies in the world, so its quarterly earnings are closely watched by investors and analysts. The approval of the new TECNIS PureSee lens also highlights the company's ongoing innovation in medical devices.

The details

Analysts are projecting Johnson & Johnson to report earnings of $2.67 per share, down from $2.77 per share in the same quarter last year. The consensus revenue estimate is $23.6 billion, up from $21.89 billion a year ago. On March 12, the company announced that the FDA had approved its TECNIS PureSee Intraocular Lens for use in cataract surgery.

  • Johnson & Johnson will release Q1 earnings before the market opens on April 14, 2026.
  • The FDA approved the TECNIS PureSee Intraocular Lens on March 12, 2026.

The players

Johnson & Johnson

A multinational corporation that develops medical devices, pharmaceutical, and consumer packaged goods.

Got photos? Submit your photos here. ›

The takeaway

Johnson & Johnson's upcoming earnings report will provide insight into the company's financial performance and the impact of its new medical device approvals. Investors will be closely watching to see if the company can maintain its strong position in the healthcare industry.